AilsynBio and Dong-E-E-Jiao Partner to Advance AI-Driven Traditional Chinese Medicine Research
Key Insights
AilsynBio (search), an AI-driven drug discovery company, signed a project cooperation agreement with Dong-E-E-Jiao Co., Ltd. to integrate artificial intelligence with traditional Chinese medicine development.
The partnership will focus on three key areas: advancing AI-driven innovation in drug discovery, launching specialized research on Premature Ovarian Insufficiency (search) (POI), and promoting cross-border fusion of biotechnology with traditional medicine.
The collaboration aims to transform traditional Chinese medicine from empirical medicine to evidence-based medicine, with specific focus on strengthening the scientific foundation of Compound E-Jiao Syrup (search) for women's health applications.
AilsynBio (search), an AI-native biotechnology company, announced a strategic partnership with Dong-E-E-Jiao Co., Ltd. (000423.SZ) at a signing ceremony held at Hong Kong Science Park on April 10, 2026. The collaboration represents a significant cross-sector integration of artificial intelligence and traditional Chinese medicine, aimed at empowering biopharmaceutical innovation through advanced technological approaches.
The ceremony brought together influential leaders from industry, academia, and research sectors, including senior representatives from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation (search) (HKSTP), and The University of Hong Kong (HKU).
Strategic Focus on AI-Enhanced Traditional Medicine
Dr. Bo Chen, Chief Scientific Officer of China Resources Pharmaceutical, emphasized the collaboration's significance in modernizing Traditional Chinese Medicine (TCM). "This collaboration with Dong-E-E-Jiao and AilsynBio (search) is a key initiative for China Resources Pharmaceutical in advancing the modernization of Traditional Chinese Medicine," Dr. Chen stated. "It represents a deep integration of industry, academia, and research in the field of 'AI + TCM' between Mainland China and Hong Kong. We look forward to leveraging scientific research and industrial resources from both regions to overcome the challenges of TCM's mechanisms of action and to pave an innovative path for TCM to evolve from empirical medicine to evidence-based medicine."
Mr. Liang Zheng, Vice President of Dong-E-E-Jiao, highlighted the partnership's role in advancing the company's core products. "As a core strategic product for Dong-E-E-Jiao, deepening the scientific value of Compound E-Jiao Syrup (search) is crucial for our brand upgrade," Zheng explained. "This cooperation will strengthen the scientific foundation of our products in the field of women's health, helping Dong-E-E-Jiao accelerate into a new stage of 'reshaping TCM wisdom through technological innovation.'"
Three-Pronged Collaborative Approach
The partnership will focus on three key collaborative directions that leverage AilsynBio (search)'s AI capabilities with Dong-E-E-Jiao's traditional medicine expertise:
Advancing AI-driven innovation: The collaboration will leverage AilsynBio (search)'s AI drug discovery platform to accelerate biopharmaceutical research and development processes, potentially reducing the time and cost associated with traditional drug development approaches.
Launching specialized research: The partnership will engage in in-depth cooperation on Premature Ovarian Insufficiency (search) (POI) research, representing a targeted therapeutic focus that aligns with Dong-E-E-Jiao's emphasis on women's health applications.
Promoting cross-border fusion: The collaboration aims to explore the integration of biotechnology, artificial intelligence, and traditional medicine to create new paradigms for the health industry.
Academic and Industry Support
Mr. Pierre Wang, Managing Director of HKU Versitech Limited (search), praised the partnership as an exemplar of successful technology transfer. "HKU Versitech is honored to witness this project cooperation between HKU spin-off AilsynBio (search) Ltd. and China Resources Pharmaceutical subsidiary Dong-E E-Jiao, a partnership that exemplifies the successful translation of Hong Kong's top-tier academic research into high-impact industrial applications," Wang stated. "This cooperation will continue to serve as a vital catalyst for the company's rapid international growth and its mission to scale cutting-edge biotechnology globally."
The agreement signing was witnessed by Dr. Bo Chen, Chief Scientist of China Resources Pharmaceutical; Mr. Eric Or, Chief Ecosystem Development Officer of HKSTP; and Mr. Pierre Wang, Managing Director of HKU Versitech.
Technology Platform and Capabilities
AilsynBio (search) brings to the partnership its AI-native biotechnology platform that combines artificial intelligence, physics-based modeling, and deep medicinal chemistry expertise. The company's technology offers end-to-end drug discovery solutions spanning novel target identification, mechanism-of-action elucidation, and lead design and optimization. According to the company, its platform has been validated through collaborations with multiple top-tier pharmaceutical companies and offers industry-leading predictive accuracy while enabling the delivery of IND-ready candidate molecules with greater efficiency and higher success rates.
Dong-E-E-Jiao, established in 1952 and listed on the Shenzhen Stock Exchange in 1996, operates as a subsidiary of state-owned China Resources Group. The company is primarily engaged in research and development, production, and sales of E-Jiao and related Chinese patent medicines, health foods, and food products. The company houses the National Gelatin Traditional Chinese Medicine Engineering Technology Research Center and maintains recognition as a National High-Tech Enterprise and National Innovative Enterprise.
AilsynBio (search) characterized the cooperation as both a combination of cutting-edge technology and traditional medicine and a strategic layout for future healthcare innovation, stating that the partnership aims to inject technological vitality into traditional medicine for the benefit of more patients.